EP Lab

This channel includes news and new technology innovations for cardiac electrophysiology (EP) systems, techniques and devices using in EP labs. This includes implantable EP devices, pacemakers, implantable cardioverter defibrillators (ICD), cardiac resychronization therapy (CRT), ablation technologies, left atrial appendage (LAA) occlusion, atrial fibrilation (AF) and Holter monitors.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.
Feature | Artificial Intelligence

The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work ...

Home June 10, 2021
Home
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.
Feature | ACC | By Dave Fornell, Editor

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

Home June 08, 2021
Home
News | EP Lab

June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions ...

Home June 02, 2021
Home
News | EP Lab

May 25, 2021 — Acutus Medical Inc. announced European CE mark approval for a broad suite of electrophysiology (EP) produ ...

Home May 25, 2021
Home
News

May 25, 2021 — iRhythm Technologies Inc. announced two new U.S. Food and Drug Administration (FDA) 510(k) clearances — ...

Home May 25, 2021
Home
Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions. 
Feature | EP Lab | By Dave Fornell, Editor

May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...

Home May 16, 2021
Home
The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman
Feature | Left Atrial Appendage (LAA) Occluders

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

Home May 16, 2021
Home
News | Left Atrial Appendage (LAA) Occluders

May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib) ...

Home May 15, 2021
Home
News | EP Lab

May 14, 2021 — The U.S. Food and Drug Administration (FDA) is advising patients and caregivers to keep any consumer ...

Home May 14, 2021
Home
News | EP Lab

May 14, 2021 — Abbott is recalling a subset of Assurity and Endurity pacemakers built using specific manufacturing ...

Home May 14, 2021
Home
News | EP Lab

May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation ...

Home May 12, 2021
Home
News | Wearables

May 6, 2021 — The wearable cardiac devices market is set to grow from its current market was valued at more than $1.2 ...

Home May 06, 2021
Home
News | EP Lab

May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of ...

Home May 06, 2021
Home
News | EP Lab

April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for ...

Home April 26, 2021
Home
Subscribe Now